Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: Inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma

Molecular Cancer Therapeutics

Volumn 8, Issue 10, 2009, Pages 2803-2810

  Gao, Chong Feng ^a   Xie, Qian ^a   Zhang, Yu Wen ^a   Su, Yanli ^a   Zhao, Ping ^a   Cao, Brian ^a   Furge, Kyle ^a   Sun, Jan ^b,c   Rex, Karen ^b,c   Osgood, Tao ^b,c   Coxon, Angela ^b,c   Burgess, Teresa L ^b,c   Vande Woude, George F ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b AMGEN INC   (United States)

^c Department Oncology Research ^*

Author keywords

[No Author keywords available]

Indexed keywords

AMG 102; IMMUNOGLOBULIN G2; MONOCLONAL ANTIBODY; RECOMBINANT SCATTER FACTOR; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOCRINE EFFECT; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CELL ASSAY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN SK LMS 1; CONTROLLED STUDY; EXPERIMENTAL MOUSE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEIOMYOSARCOMA; MOUSE; NONHUMAN; NUDE MOUSE; PARACRINE SIGNALING; PRIORITY JOURNAL; TRANSGENICS;

ANIMALS; ANTIBODIES, NEUTRALIZING; AUTOCRINE COMMUNICATION; CELL LINE; CELL PROLIFERATION; FIBRINOLYSIN; HEPATOCYTE GROWTH FACTOR; HUMANS; LEIOMYOSARCOMA; LIGANDS; MICE; MICE, TRANSGENIC; MODELS, IMMUNOLOGICAL; NEOPLASM INVASIVENESS; PARACRINE COMMUNICATION; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70350228630     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0125     Document Type: Article

References (22)

1. Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2002;2:289-300. (Pubitemid 37328782)
2. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-925
3. Hepatocyte growth factor/scatter factor, Met and cancer references. In: V. A. Institute (ed.). Grand Rapids.
4. Knudsen BS, Vande Woude G. Showering c-MET-dependent cancers with drugs. Curr Opin Genet Dev 2008;18:87-96.
5. Zhang YW, Graveel C, Shinomiya N, Vande Woude GF. Met decoys: will cancer take the bait? Cancer Cell 2004;6:5-6.
6. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008;7:504-516 (Pubitemid 351767118)
7. Rong S, Jeffers M, Resau JH, Tsarfaty I, Oskarsson M, Vande Woude GF. Met expression and sarcoma tumorigenicity. Cancer Res 1993;53: 5355-5360
8. Burgess T, Coxon A, Meyer S, et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 2006;66: 1721-1729 (Pubitemid 43259957)
9. Jun HT, Sun J, Rex K, et al. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res 2007;13:6735-6742 (Pubitemid 350206811)
10. Martens T, Schmidt NO, Eckerich C, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006; 12:6144-6152 (Pubitemid 44703780)
11. Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007;67: 4408-4417 (Pubitemid 46815090)
12. Cao B, Su Y, Oskarsson M, et al. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci U S A 2001;98: 7443-7448 (Pubitemid 32567968)
13. Kim K, Hur Y, Ryu EK, et al. A neutralizable epitope is induced on HGF upon its interaction with its receptor cMet. Biochem Biophys Res Commun 2007;354:115-121 (Pubitemid 46123209)
14. Kim KJ, Wang L, Su YC, et al. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res 2006;12:1292-1298 (Pubitemid 43342521)
15. Rong S, Oskarsson M, Faletto D, et al. Tumorigenesis induced by co-expression of human hepatocyte growth factor and the human met proto-oncogene leads to high levels of expression of the ligand and receptor. Cell Growth Differ 1993;4:563-569
16. Zhang YW, Su Y, Lanning N, et al. Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor. Oncogene 2005;24:101-106 (Pubitemid 40143869)
17. Jeffers M, Rong S, Vande Woude GF. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biol 1996;16:1115-1125 (Pubitemid 26061683)
18. Xie Q, Gao CF, Shinomiya N, et al. Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion. Oncogene 2005;24:3697-3707 (Pubitemid 40826869)
19. Webb CP, Hose CD, Koochekpour S, et al. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-meturokinase plasminogen activator-plasmin proteolytic network. Cancer Res 2000;60:342-349 (Pubitemid 30070761)
20. Gao CF, Xie Q, Su YL, et al. Proliferation and invasion: plasticity in tumor cells. Proc Natl Acad Sci U S A 2005;102:10528-10533 (Pubitemid 41061588)
21. Kirchhofer D, Yao X, Peek M, et al. Structural and functional basis of the serine protease-like hepatocyte growth factor β-chain in Met binding and signaling. J Biol Chem 2004;279:39915-39924 (Pubitemid 39258264)
22. Stabile LP, Rothstein ME, Keohavong P, et al. Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis. Mol Cancer Ther 2008;7:1913-1922